https://goo.gl/fh8ujb
It's not particularly hard to win a new game called EpiPen Tycoon: As Mylan CEO Heather Bresch, you just jack up drug prices to keep investors happy and boost your salary. If public outrage rises too high, you just wait it out—or press a button to "Call Your Dad (Senator)" or "Offer Generic Version."
It's a tidy simplification of the real story. Mylan raised prices on EpiPen packs 400% since 2007, from $57 to $600; Bresch's compensation rose as the drug price did, from $2,453,456 in 2007 to $18,931,068 in 2015. When customers became angry enough, and a petition quickly gathered more than 100,000 signatures, Mylan eventually announced that it would roll out a $300 generic version.